Opioid Use, Unspecified Clinical Trial
Official title:
Evaluation of Fentalogs and Their Metabolites in Hair of Patients in a Monitored Clinical Context by Means of Hair Analysis
The goal of this fundamental research study is to learn how opioids are incorporated into hair after application of opioids to newborns, infants and children in a controlled medical setting. The main questions aimed to answer are: Are opioids (specifically fentalogs) incorporated into hair? Are opioids detectable in sweat and does sweat influence the incorporation into hair? Can normative opioid value ranges be established in hair? Can these values help to for interpretation of opioid positive hair results and ultimately help distinguish between medical opioid intake and intake of illegal designer opioids? Hair samples from 150 patients will be taken as well as 75 sweat sample and analyzed for their opioid concentrations. Investigators hypothesize that opioids will be detectable in hair and sweat and that the cohort size will allow to establish normative value ranges that will help for interpretation of hair results in forensic toxicology.
In recent years, new synthetic opioids (NSOs) have emerged in the illicit drug supply in an increasing rate. Many of these new registered opioids can structurally be assigned to the so called fentalogs, which are pharmacologically active derivatives of the approved pain management drug fentanyl. Many of these compounds are highly potent, relatively cheap and thereby especially fueling the current opioid crisis in the USA and posing a significant challenge for authorities, the healthcare system and forensic toxicology globally. Most of the time opioids are consumed without the user's knowledge as they are sold as heroin or counterfeit prescription pills like oxycodone or Xanax® which further increases the dangers posed by this problematic substance class. Recent cases of designer fentanyl intoxication show that this problem is also encountering Switzerland. Due to their potency, overdoses of the above-mentioned substances quickly occur, which in absence of intensive medical support can be fatal even when the antagonist naloxone is used. In order to better address the NSOs related socio-economic and health care problems, a fundamental understanding of these substance classes is essential. As a consequence of the increasing prevalence of designer opioids, forensic and clinical laboratories worldwide are continuously challenged with updating their analytical methods for the identification and quantification of these new drugs in various biological matrices. The classical matrices used in forensic toxicology are blood and urine which represent time windows of hours to days. Keratinized matrices like hair and nail are considered complementary matrices as they provide additional information to the more traditional matrices covering time windows up to several months. The analysis of hair (a keratinized matrix) can provide significant information about the intake of opioids over extended time periods and therefore can provide access to a much wider diagnostic window than blood or urine. It allows getting information about a past exposure to the substance, repeated intake or even a single intake. According to the Swiss Society of Legal Medicine, Swiss laboratories that offer forensic hair analysis must be able to quantify opioids in hair. The analysis of classical opioids like morphine and respective metabolites is well established in hair. However, knowledge about the incorporation of medically used fentalogs (e.g. fentanyl, remifentanil and sufentanil) and illegal designer fentalogs in hair is still limited. The goal of this study is to gain knowledge about the incorporation and concentration of fentalogs in hair to help establish a high forensic standard for the detection these new substances. The specific aim of this study is to analyze hair samples from patients (children) of a study cohort described below which received medically approved fentalogs (either fentanyl, remifentanil or sufentanil) and to gain insights into the deposition of these substances into hair. The investigators will focus on a study cohort (150 patients) that has received medical fentanyl for pain management therapy in a clinical and therefore controlled setting. Furthermore, the study cohort consists of children which have some benefits to address the above raised research question. The hair of children is thinner and more porous than adult's hair, so that substances can incorporate into hair more easily. This makes children's hair an ideal target for our research study to see if fentalogs will be incorporated into hair. Furthermore, it is known that cosmetic treatment like e.g. bleaching etc. destroys substance that are incorporated in hair, therefore cosmetically treated hair is not suitable for the study. The probability that young children have cosmetically treated hair is considered very low. As substances are incorporated into hair via sweat and blood, the analysis of these matrices can help to understand the general incorporation mechanisms of substances into hair. Therefore, the investigators intend to additionally analyze sweat samples from children to gain knowledge about fentalog concentrations and metabolites in sweat which can be helpful to understand their incorporation into hair. The knowledge of this study can be used in forensic toxicology to distinguish between the intake of medically prescribed opioids and illegal new synthetic opioids. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02747875 -
Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT02244099 -
Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic
|
N/A | |
Recruiting |
NCT03923374 -
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
|
||
Completed |
NCT04069403 -
An Opioid Prescribing Nudge
|
N/A | |
Completed |
NCT04155229 -
EMR Defaults to Nudge Opioid Prescribing
|
N/A | |
Completed |
NCT02299024 -
Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter
|
N/A | |
Recruiting |
NCT04564729 -
Shared Decision Aid for Post-Total Knee Arthroplasty Opioid Prescribing
|
N/A | |
Recruiting |
NCT05283980 -
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
|
Phase 2/Phase 3 | |
Completed |
NCT04854551 -
Opioid Modulation and Neural Reward Activation in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT06050551 -
Pigtail or Chest Tube Placement After Uniportal Video-assisted Thoracoscopic Surgery
|
N/A | |
Completed |
NCT04928339 -
Pecto-Intercostal Fascial Plane Block Study
|
Phase 4 | |
Completed |
NCT03773484 -
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase
|
N/A | |
Completed |
NCT02653144 -
the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block
|
Phase 4 | |
Enrolling by invitation |
NCT05875857 -
Patient Utilization of Opioid Destruction Bags in the Post op Period
|
N/A | |
Recruiting |
NCT04275258 -
Collaborative Opioid Taper After Trauma: Preventing Opioid Misuse and Opioid Use Disorder
|
N/A | |
Completed |
NCT04252443 -
Nurses' Knowledge and Attitude About Opioids
|
N/A | |
Recruiting |
NCT05242081 -
Study on Opioid-free Anesthesia Protocol With S-ketamine and Propofol
|
N/A | |
Completed |
NCT02431793 -
EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use
|
N/A | |
Completed |
NCT03959969 -
Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery
|
N/A |